PT-141 (Bremelanotide)
Technical Monograph
PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). It is primarily researched for its role in central nervous system-mediated sexual arousal.
Mechanism of Action
Unlike phosphodiesterase type 5 (PDE5) inhibitors that act solely on vascular pathways, PT-141 agonizes melanocortin receptors (MC3R and MC4R) primarily in the hypothalamus to stimulate neurogenic arousal.
Pharmacological Detail
By directly passing through the blood-brain barrier and binding to MC4 receptors in the medial preoptic area, it initiates a neurochemical cascade responsible for desire and arousal.
Pharmacodynamics
Elicits marked autonomic and somatic responses independently of external psychogenic stimulation.
Pharmacokinetics
Onset of action is highly variable (2 to 6 hours). Biological activity may persist up to 24-72 hours in some study models.
Preclinical Observations & In Vitro Data
FDA-approved (as Vyleesi) for female sexual arousal pathways. Data cited from broad published clinical literature; not a product claim.
Abstract Highlights
- Central nervous system pathway activation documented
- Efficacy reported irrespective of vascular compromise
- Significant activity in both male and female study models
- Induction of spontaneous neurogenic arousal observed
Chemical Specifications
Material Handling & Stability
Strict Notice
THIS COMPOUND IS PRODUCED FOR LABORATORY RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION. MATERIAL DATA SHEETS AND LABORATORY GUIDELINES SHOULD BE CONSULTED PRIOR TO HANDLING.